Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers: A Secondary Analysis of a Randomized Clinical Trial

• Published in: Archives of neurology (Chicago) Vol. 81; no. 2; p. 197
• Main Authors: Brum, Wagner S, Docherty, Kieran F, Ashton, Nicholas J, Zetterberg, Henrik, Hansson, Oskar, McMurray, John J V, Blennow, Kaj
• Format: Journal Article
• Language: English
• Published: United States American Medical Association 01.02.2024
• Subjects: Alzheimer Disease - drug therapy; Alzheimer's disease; Angiotensin Receptor Antagonists; Biomarkers; Blood; Clinical trials; Creutzfeldt-Jakob disease; Demographics; Drug Combinations; Drug interaction; Drug interactions; Heart Failure; Humans; Neprilysin; Neurodegenerative diseases; Population studies; Secondary analysis
• ISSN: 2168-6149; 2168-6157
• DOI: 10.1001/jamaneurol.2023.4719

The reported incidence of Creutzfeldt-Jakob disease (CJD) has increased significantly, particularly among older individuals and females. This trend aligns with data from Japan and may be influenced by changing demographics and improved detection methods. However, the reliance on death certificate data for estimating CJD incidence is a limitation, as it may be subject to miscoding or misdiagnosis. The study highlights the need for enhanced surveillance and monitoring of CJD among the aging US population. In another study, the effect of neprilysin inhibition on Alzheimer's disease (AD) plasma biomarkers was examined. The study found that sacubitril/valsartan, a neprilysin inhibitor, increased plasma 40 levels, which could potentially confound AD blood tests. The findings suggest that caution should be exercised when interpreting AD blood test results in patients receiving sacubitril/valsartan, as the drug may lead to false-positive results. Multibiomarker assessments may be more effective in controlling for factors that affect individual biomarkers. Further studies are needed to explore the potential drug interaction and its implications for AD diagnosis.